TG 4010

Drug Profile

TG 4010

Alternative Names: Cancer vaccine - Transgene; MVA-MUC1-IL2; TG-4010; TG4010 MUC-1 targeted immunotherapy; VV-MUC-IL2

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Transgene
  • Developer Transgene; University of California, Davis
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Interleukin 12 stimulants; Mucin 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • Suspended Prostate cancer; Renal cell carcinoma
  • Discontinued Breast cancer

Most Recent Events

  • 04 Jan 2017 Transgene terminates phase IIb/III trial in Non-small cell lung cancer in USA, Israel, Belgium, France, Germany, Hungary, Italy, Poland, Spain and the United Kingdom due to undisclosed reasons (NCT01383148)
  • 19 Dec 2016 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (SC) (NCT02823990)
  • 05 Sep 2016 Transgene plans a phase II trial for Non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top